BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30021167)

  • 1. CIP2A Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer's Disease.
    Shentu YP; Huo Y; Feng XL; Gilbert J; Zhang Q; Liuyang ZY; Wang XL; Wang G; Zhou H; Wang XC; Wang JZ; Lu YM; Westermarck J; Man HY; Liu R
    Cell Rep; 2018 Jul; 24(3):713-723. PubMed ID: 30021167
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chk1 Inhibition Ameliorates Alzheimer's Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A Signaling.
    Hu W; Wang Z; Zhang H; Mahaman YAR; Huang F; Meng D; Zhou Y; Wang S; Jiang N; Xiong J; Westermarck J; Lu Y; Wang J; Wang X; Shentu Y; Liu R
    Neurotherapeutics; 2022 Mar; 19(2):570-591. PubMed ID: 35286657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genistein Decreases APP/tau Phosphorylation and Ameliorates Aβ Overproduction Through Inhibiting CIP2A.
    Shentu YP; Hu WT; Liang JW; Liuyang ZY; Wei H; Qun W; Wang XC; Wang JZ; Westermarck J; Liu R
    Curr Alzheimer Res; 2019; 16(8):732-740. PubMed ID: 31470788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyphyllin I attenuates cognitive impairments and reduces AD-like pathology through CIP2A-PP2A signaling pathway in 3XTg-AD mice.
    Zhou Y; Yang D; Chen H; Zheng C; Jiang H; Liu X; Huang X; Ye S; Song S; Jiang N; Zhao Z; Ma S; Ma J; Huang K; Chen C; Fan X; Gong Y; Wang X; Fan J; Liu R; Shentu Y
    FASEB J; 2020 Dec; 34(12):16414-16431. PubMed ID: 33070372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ChK1 activation induces reactive astrogliosis through CIP2A/PP2A/STAT3 pathway in Alzheimer's disease.
    Zhou Y; Liu X; Ma S; Zhang N; Yang D; Wang L; Ye S; Zhang Q; Ruan J; Ma J; Wang S; Jiang N; Zhao Z; Zhao S; Zheng C; Fan X; Gong Y; Abdoul Razak MY; Hu W; Pan J; Wang X; Fan J; Li J; Liu R; Shentu Y
    FASEB J; 2022 Mar; 36(3):e22209. PubMed ID: 35195302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CIP2A-promoted astrogliosis induces AD-like synaptic degeneration and cognitive deficits.
    Shentu YP; Hu WT; Zhang Q; Huo Y; Liang JW; Liuyang ZY; Zhou H; Wei H; Ke D; Wang XC; Wang JZ; Man HY; Westermarck J; Liu R
    Neurobiol Aging; 2019 Mar; 75():198-208. PubMed ID: 30594047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurofibrillary tangle formation by introducing wild-type human tau into APP transgenic mice.
    Umeda T; Maekawa S; Kimura T; Takashima A; Tomiyama T; Mori H
    Acta Neuropathol; 2014 May; 127(5):685-98. PubMed ID: 24531886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Protein Phosphatase-2A (PP2A) by I1PP2A Leads to Hyperphosphorylation of Tau, Neurodegeneration, and Cognitive Impairment in Rats.
    Wang X; Blanchard J; Tung YC; Grundke-Iqbal I; Iqbal K
    J Alzheimers Dis; 2015; 45(2):423-35. PubMed ID: 25589718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SET SUMOylation promotes its cytoplasmic retention and induces tau pathology and cognitive impairments.
    Qin M; Li H; Bao J; Xia Y; Ke D; Wang Q; Liu R; Wang JZ; Zhang B; Shu X; Wang X
    Acta Neuropathol Commun; 2019 Feb; 7(1):21. PubMed ID: 30767764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease.
    Kirouac L; Rajic AJ; Cribbs DH; Padmanabhan J
    eNeuro; 2017; 4(2):. PubMed ID: 28374012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolfenamic acid inhibits GSK-3β and PP2A mediated tau hyperphosphorylation in Alzheimer's disease models.
    Zhang H; Wang X; Xu P; Ji X; Chi T; Liu P; Zou L
    J Physiol Sci; 2020 Jun; 70(1):29. PubMed ID: 32517647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLZ alleviates the memory deficits in transgenic mouse model of Alzheimer's disease via decreasing beta-amyloid production and tau hyperphosphorylation.
    Bao XQ; Li N; Wang T; Kong XC; Tai WJ; Sun H; Zhang D
    PLoS One; 2013; 8(11):e78033. PubMed ID: 24223757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The flavonoid baicalein rescues synaptic plasticity and memory deficits in a mouse model of Alzheimer's disease.
    Gu XH; Xu LJ; Liu ZQ; Wei B; Yang YJ; Xu GG; Yin XP; Wang W
    Behav Brain Res; 2016 Sep; 311():309-321. PubMed ID: 27233830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of microtubule-associated protein tau phosphorylation in Alzheimer's disease.
    Ma RH; Zhang Y; Hong XY; Zhang JF; Wang JZ; Liu GP
    J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):307-312. PubMed ID: 28585125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudoginsenoside-F11 alleviates cognitive deficits and Alzheimer's disease-type pathologies in SAMP8 mice.
    Zhang Z; Yang J; Liu C; Xie J; Qiu S; Yang X; Wu C
    Pharmacol Res; 2019 Jan; 139():512-523. PubMed ID: 30394318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction between NH(2)-tau fragment and Aβ in Alzheimer's disease mitochondria contributes to the synaptic deterioration.
    Amadoro G; Corsetti V; Atlante A; Florenzano F; Capsoni S; Bussani R; Mercanti D; Calissano P
    Neurobiol Aging; 2012 Apr; 33(4):833.e1-25. PubMed ID: 21958963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APP/PS1 mice overexpressing SREBP-2 exhibit combined Aβ accumulation and tau pathology underlying Alzheimer's disease.
    Barbero-Camps E; Fernández A; Martínez L; Fernández-Checa JC; Colell A
    Hum Mol Genet; 2013 Sep; 22(17):3460-76. PubMed ID: 23648430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing PP2A inhibitor by lenti-shRNA interference ameliorates neuropathologies and memory deficits in tg2576 mice.
    Liu GP; Wei W; Zhou X; Shi HR; Liu XH; Chai GS; Yao XQ; Zhang JY; Peng CX; Hu J; Li XC; Wang Q; Wang JZ
    Mol Ther; 2013 Dec; 21(12):2247-57. PubMed ID: 23922015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correcting abnormalities in miR-124/PTPN1 signaling rescues tau pathology in Alzheimer's disease.
    Hou TY; Zhou Y; Zhu LS; Wang X; Pang P; Wang DQ; Liuyang ZY; Man H; Lu Y; Zhu LQ; Liu D
    J Neurochem; 2020 Aug; 154(4):441-457. PubMed ID: 31951013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ.
    Ittner A; Asih PR; Tan ARP; Prikas E; Bertz J; Stefanoska K; Lin Y; Volkerling AM; Ke YD; Delerue F; Ittner LM
    Acta Neuropathol; 2020 Sep; 140(3):279-294. PubMed ID: 32725265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.